MarketCap
Facebook
X
Telegram
Novo Nordisk A/S Market Cap | NVO
As of October 06, 2026 Novo Nordisk A/S has a market cap of $ 167 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Novo Nordisk A/S
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 219 B | 384 B | 543 B | 830 B | 257 B | 163 B | 132 B | 114 B | 140 B | 90.3 B | 144 B | 117 B | 103 B | 101 B | 65.7 B |
All numbers in DKK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 830 B | 65.7 B | 227 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Catalyst Biosciences
CBIO
|
999 M | $ 13.94 | 0.42 % | $ 1.25 B |  USA |
 |
C4 Therapeutics
CCCC
|
234 M | $ 2.99 | 1.36 % | $ 248 M | USA |
 |
Codexis
CDXS
|
111 M | $ 1.39 | 2.21 % | $ 121 M | USA |
 |
Cerus Corporation
CERS
|
496 M | $ 2.34 | 2.63 % | $ 446 M | USA |
 |
Certara
CERT
|
1.08 B | $ 10.07 | 7.59 % | $ 1.62 B | USA |
 |
Cullinan Management
CGEM
|
898 M | $ 16.04 | 3.42 % | $ 966 M | USA |
 |
Compugen Ltd.
CGEN
|
196 M | $ 2.31 | 0.43 % | $ 216 M |  Israel |
 |
Coherus BioSciences
CHRS
|
226 M | $ 1.12 | 0.86 % | $ 131 M | USA |
 |
Celldex Therapeutics
CLDX
|
2.04 B | $ 32.59 | 2.97 % | $ 2.16 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
4.64 M | $ 3.41 | 1.46 % | $ 41.6 M | Israel |
 |
Cellectis S.A.
CLLS
|
335 M | $ 1.41 | 0.48 % | $ 141 M |  France |
 |
Cellectar Biosciences
CLRB
|
7.49 M | $ 1.67 | 0.56 % | $ 4.36 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
1.06 M | $ 5.3 | 0.7 % | $ 2.35 M | USA |
 |
Cocrystal Pharma
COCP
|
11.4 M | $ 1.11 | 1.72 % | $ 12.5 M | USA |
 |
Collegium Pharmaceutical
COLL
|
1.4 B | $ 21.87 | 0.05 % | $ 692 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
3.75 B | $ 122.03 | 4.99 % | $ 12.7 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
127 M | $ 5.85 | 0.16 % | $ 77.9 M | USA |
 |
Cardiff Oncology
CRDF
|
116 M | $ 1.14 | 1.79 % | $ 76.2 M | USA |
 |
Curis
CRIS
|
9.48 M | $ 0.79 | 0.1 % | $ 10.4 M | USA |
 |
CorMedix
CRMD
|
456 K | $ 7.26 | 0.97 % | $ 523 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
4.39 B | $ 57.34 | 3.45 % | $ 5.16 B |  Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
318 M | $ 10.74 | 0.09 % | $ 848 M | USA |
 |
Champions Oncology
CSBR
|
83.8 M | $ 4.97 | 0.61 % | $ 68.7 M | USA |
 |
CytomX Therapeutics
CTMX
|
931 M | $ 2.58 | 0.78 % | $ 356 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
8.52 M | $ 0.52 | 0.4 % | $ 5.75 M | USA |
 |
Cue Biopharma
CUE
|
29.4 M | $ 24.36 | 1.27 % | $ 2.31 B | USA |
 |
CEL-SCI Corporation
CVM
|
19.9 M | $ 2.42 | 4.76 % | $ 19.4 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
7.55 M | $ 62.7 | 0.2 % | $ 7.53 M | USA |
 |
Daré Bioscience
DARE
|
16.9 M | $ 0.84 | 0.04 % | $ 9.39 M | USA |
 |
DBV Technologies S.A.
DBVT
|
2.82 B | $ 10.44 | 0.47 % | $ 1.46 B | France |
 |
DiaMedica Therapeutics
DMAC
|
312 M | $ 8.42 | 2.31 % | $ 396 M | USA |
 |
Denali Therapeutics
DNLI
|
2.41 B | $ 19.91 | 0.41 % | $ 3.44 B | USA |
 |
Precision BioSciences
DTIL
|
64.6 M | $ 6.31 | 0.16 % | $ 80.9 M | USA |
 |
Dyadic International
DYAI
|
31.5 M | $ 0.45 | 0.31 % | $ 16.3 M | USA |
 |
Editas Medicine
EDIT
|
206 M | $ 2.79 | 6.49 % | $ 248 M | USA |
 |
Edesa Biotech
EDSA
|
11.3 M | $ 3.91 | 1.3 % | $ 22.2 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
43.9 M | $ 0.36 | 0.36 % | $ 16.5 M | Israel |
 |
Enanta Pharmaceuticals
ENTA
|
259 K | $ 12.6 | 0.93 % | $ 269 K | USA |
 |
Entera Bio Ltd.
ENTX
|
89.6 M | $ 2.62 | 0.69 % | $ 121 M | Israel |
 |
Equillium
EQ
|
118 M | $ 1.45 | 2.84 % | $ 83.1 M | USA |
 |
Eton Pharmaceuticals
ETON
|
559 M | $ 55.62 | 0.47 % | $ 1.5 B | USA |
 |
Evogene Ltd.
EVGN
|
6.38 M | $ 0.4 | 3.54 % | $ 3.15 M | Israel |
 |
Exelixis
EXEL
|
11.7 B | $ 58.85 | 0.79 % | $ 16 B | USA |
 |
EyePoint Pharmaceuticals
EYPT
|
1.15 M | $ 3.15 | 0.62 % | $ 231 K | USA |
 |
Fate Therapeutics
FATE
|
187 M | $ 2.43 | 4.74 % | $ 289 M | USA |
 |
Fortress Biotech
FBIO
|
77.8 M | $ 2.09 | 2.96 % | $ 58.3 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
169 M | $ 10.62 | 4.12 % | $ 303 M | USA |
 |
Fulcrum Therapeutics
FULC
|
539 M | $ 3.71 | 0.54 % | $ 235 M | USA |
 |
Merus N.V.
MRUS
|
2.98 B | - | - | $ 5.78 B |  Niderland |
 |
Galectin Therapeutics
GALT
|
178 M | $ 3.73 | 3.72 % | $ 238 M | USA |